Alcyomics has developed, a novel a non-artificial (non-3D), human skin explant in vitro assay (SkimuneT) which predicts adverse immune responses to drugs, chemicals, novel 'cosmeceuticals' and monoclonal antibodies with the potential to replace/reduce animal testing and save development time. SkimuneT is unique in its ability to assess the efficacy of new biologics (monoclonal antibodies) and allow comparative studies with Biosimilars and Biobetters. The Alcyomics service targets pharmaceutical, cosmetics and chemical industries, with contracts from large pharma, as well as Institutes and contract research organisations. Innovative histopathology read-out of skin damage assesses potency and correlates with systemic disease